Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

Happy Friday to Barchart readers, everywhere. I don’t know what the weather is like where you live, but here in Halifax, on ...

Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon ...

New numbers show a 50% spike in prescriptions for the weight-loss drug Wegovy in the past year. Some doctors say the drug is ...

Blockbuster weight loss jabs could make contraception less effective, and prove harmful to unborn babies, according to an ...